

Mr. Kevin Null
Materials Licensing Branch
U. S. Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

January 15, 2014

Re: Information commitments related to Materials License 21-11315-02 amendment to possess activation products contained in cyclotron previously operated by Pfizer (C/N 582622), as discussed in telephone conversation on 01/15/2014

Dear Mr. Null,

Thanks for taking the time today to discuss our license amendment application for possession of activation products contained in the cyclotron we wish to acquire from Pfizer. As we discussed, MPI Research commits to providing the following information:

1. Results of the most recent survey for radiation levels around the self-shielded cyclotron performed by Pfizer.
2. Results of the most recent survey for removable contamination conducted on the self-shielded cyclotron performed by Pfizer.
3. Results of radiation level surveys around the self-shielded cyclotron, performed by MPI Research, after receipt and installation of the device.
4. Results of radiation level surveys in rooms/areas adjacent to the room where the cyclotron will be stored after the cyclotron is enclosed in its room at MPI Research.


We understand that items 1 and 2 above must be submitted to you for your review before the approved amendment allowing possession is released to us. We will perform items 3 and 4 above as soon as possible after receipt and installation of the device and submit the results to you.

In addition, we discussed financial assurance arrangements for possession of the activation products. MPI Research will be submitting separate stand-alone financial assurance for the long-lived activation products in the cyclotron and associated with operation of the cyclotron with our application for a production license, which will be submitted in the near future. In that application we will explain that the production license financial assurance will take the place of the financial assurance provided in the

broad scope license amendment for possession of the cyclotron activation products, and we will request at that time that the trust agreement we have put in place for the broad scope license amendment (C/N 582622) be cancelled and returned to MPI Research.

We are currently making arrangements to obtain items 1 and 2 above, and will forward those as quickly as possible. Please call me at 269-668-3336 ext. 2050, if there is any information you may need beyond what we discussed today.

Best regards,



Richard Granberg, RSO
MPI Research, Inc.